{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T02:52:36Z","timestamp":1788835956955,"version":"build-2803163510"},"posted":{"date-parts":[[2026,6,16]]},"group-title":"Immunology","reference-count":89,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T00:00:00Z","timestamp":1781568000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"award":["R01AI186721"],"award-info":[{"award-number":["R01AI186721"]}],"id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R01AI179457"],"award-info":[{"award-number":["R01AI179457"]}],"id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R01OD011095"],"award-info":[{"award-number":["R01OD011095"]}],"id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"publisher"}]},{"award":["R01AI152703"],"award-info":[{"award-number":["R01AI152703"]}],"id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"publisher"}]},{"award":["P01AI169615"],"award-info":[{"award-number":["P01AI169615"]}],"id":[{"id":"https:\/\/ror.org\/043z4tv69","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,6,16]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Broadly neutralizing antibodies (bnAbs) are a promising intervention for HIV prevention, therapy, and cure. bnAb optimization requires precise quantification of\n                  <jats:italic>in vivo<\/jats:italic>\n                  functions, many of which cannot be directly measured in humans. We therefore performed a mathematical modeling meta-analysis which integrated four clinical trials and reproduced serial bnAb concentrations, viral loads, and bnAb sensitivities (IC50) in 43 viremic trial participants who received an infusion of VRC01, VRC01LS, VRC07-523LS, 3BNC117 or 10-1074. We compared &gt;300 mathematical models for their ability to recapitulate multi-strain HIV dynamics following bnAb infusion. For each bnAb, our best model identified a scaling factor of 36-462 to pro\n                  <jats:italic>j<\/jats:italic>\n                  ect\n                  <jats:italic>in vivo<\/jats:italic>\n                  activity from\n                  <jats:italic>in vitro<\/jats:italic>\n                  IC50, quantified Fc-mediated infected cell killing in humans over time, and pro\n                  <jats:italic>j<\/jats:italic>\n                  ected the timing of bnAb-resistant strain emergence. Using this holistic profile, VRC07-523-LS was generally optimal.\n                <\/jats:p>","DOI":"10.64898\/2026.06.13.732071","type":"posted-content","created":{"date-parts":[[2026,6,16]],"date-time":"2026-06-16T14:47:22Z","timestamp":1781621242000},"source":"Crossref","is-referenced-by-count":1,"title":["Modeling quantifies in vivo neutralization, Fc-mediated killing, and resistance in human clinical trials of five anti-HIV broadly neutralizing antibodies"],"prefix":"10.64898","author":[{"given":"Lucero","family":"Rodriguez Rodriguez","sequence":"first","affiliation":[{"name":"Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonah","family":"Hall","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E Fabian","family":"Cardozo-Ojeda","sequence":"additional","affiliation":[{"name":"Regeneron, White Plains, NJ"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca M","family":"Lynch","sequence":"additional","affiliation":[{"name":"Department of Microbiology, Immunology, and Tropical Medicine, The George Washington University, Washington, DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan S","family":"Perelson","sequence":"additional","affiliation":[{"name":"Theoretical Biology and Biophysics, Los Alamos National Laboratory, Los Alamos, NM"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua T","family":"Schiffer","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA"},{"name":"Department of Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5684-9538","authenticated-orcid":false,"given":"Daniel B","family":"Reeves","sequence":"additional","affiliation":[{"name":"Vaccine and Infectious Diseases Division, Fred Hutchinson Cancer Center, Seattle, WA, USA"},{"name":"Department of Global Health, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026061814000752000_2026.06.13.732071v1.1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2110275"},{"key":"2026061814000752000_2026.06.13.732071v1.2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1910993"},{"key":"2026061814000752000_2026.06.13.732071v1.3","doi-asserted-by":"crossref","first-page":"A132","DOI":"10.1016\/j.vaccine.2018.11.004","article-title":"Recent advances in the development of monoclonal antibodies for rabies post exposure prophylaxis: A review of the current status of the clinical development pipeline","volume":"37","year":"2019","journal-title":"Vaccine"},{"key":"2026061814000752000_2026.06.13.732071v1.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.chom.2020.05.010"},{"key":"2026061814000752000_2026.06.13.732071v1.5","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00542-x"},{"key":"2026061814000752000_2026.06.13.732071v1.6","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711460"},{"key":"2026061814000752000_2026.06.13.732071v1.7","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12511"},{"key":"2026061814000752000_2026.06.13.732071v1.8","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.1038\/s41590-025-02286-5","article-title":"Profiling of HIV-1 elite neutralizer cohort reveals a CD4bs bnAb for HIV-1 prevention and therapy","volume":"26","year":"2025","journal-title":"Nat. Immunol"},{"key":"2026061814000752000_2026.06.13.732071v1.9","doi-asserted-by":"publisher","DOI":"10.1093\/bmb\/58.1.19"},{"key":"2026061814000752000_2026.06.13.732071v1.10","doi-asserted-by":"publisher","DOI":"10.1016\/j.str.2025.04.016"},{"key":"2026061814000752000_2026.06.13.732071v1.11","doi-asserted-by":"crossref","first-page":"594","DOI":"10.3390\/pharmaceutics16050594","article-title":"Impact of LS Mutation on Pharmacokinetics of Preventive HIV Broadly Neutralizing Monoclonal Antibodies: A Cross-Protocol Analysis of 16 Clinical Trials in People without HIV","volume":"16","year":"2024","journal-title":"Pharmaceutics"},{"key":"2026061814000752000_2026.06.13.732071v1.12","doi-asserted-by":"publisher","DOI":"10.1126\/science.1241144"},{"key":"2026061814000752000_2026.06.13.732071v1.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00753-w"},{"key":"2026061814000752000_2026.06.13.732071v1.14","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-immunol-080219-023629"},{"key":"2026061814000752000_2026.06.13.732071v1.15","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1016\/S2352-3018(23)00051-6","article-title":"Long-acting antiretrovirals and HIV treatment adherence","volume":"10","year":"2023","journal-title":"Lancet HIV"},{"key":"2026061814000752000_2026.06.13.732071v1.16","doi-asserted-by":"crossref","unstructured":"Goyal, A. et al. Estimation of the in vivo neutralization potency of eCD4Ig and conditions for AAV-mediated production for SHIV long-term remission. Sci Adv 8, (2022).","DOI":"10.1126\/sciadv.abj5666"},{"key":"2026061814000752000_2026.06.13.732071v1.17","doi-asserted-by":"crossref","first-page":"1020","DOI":"10.1038\/s41586-025-09330-2","article-title":"Determinants of successful AAV-vectored delivery of HIV-1 bNAbs in early life","volume":"645","year":"2025","journal-title":"Nature"},{"key":"2026061814000752000_2026.06.13.732071v1.18","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1007\/s11904-025-00744-1","article-title":"Future of bNAbs in HIV Treatment","volume":"22","year":"2025","journal-title":"Curr. HIVAIDS Rep"},{"key":"2026061814000752000_2026.06.13.732071v1.19","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1016\/j.chom.2019.08.014","article-title":"A Meta-analysis of Passive Immunization Studies Shows that Serum-Neutralizing Antibody Titer Associates with Protection against SHIV Challenge","volume":"26","year":"2019","journal-title":"Cell Host and Microbe"},{"key":"2026061814000752000_2026.06.13.732071v1.20","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2031738"},{"key":"2026061814000752000_2026.06.13.732071v1.21","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.05.024"},{"key":"2026061814000752000_2026.06.13.732071v1.22","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000800"},{"key":"2026061814000752000_2026.06.13.732071v1.23","doi-asserted-by":"crossref","first-page":"e1010003","DOI":"10.1371\/journal.pcbi.1010003","article-title":"Optimizing clinical dosing of combination broadly neutralizing antibodies for HIV prevention","volume":"18","year":"2022","journal-title":"Plos Comput Biol"},{"key":"2026061814000752000_2026.06.13.732071v1.24","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-03247-5"},{"key":"2026061814000752000_2026.06.13.732071v1.25","doi-asserted-by":"crossref","first-page":"e76004","DOI":"10.7554\/eLife.76004","article-title":"Design of an optimal combination therapy with broadly neutralizing antibodies to suppress HIV-1","volume":"11","year":"2022","journal-title":"eLife"},{"key":"2026061814000752000_2026.06.13.732071v1.26","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2008190117"},{"key":"2026061814000752000_2026.06.13.732071v1.27","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2008236117"},{"key":"2026061814000752000_2026.06.13.732071v1.28","doi-asserted-by":"publisher","DOI":"10.1038\/ncomms10844"},{"key":"2026061814000752000_2026.06.13.732071v1.29","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000439"},{"key":"2026061814000752000_2026.06.13.732071v1.30","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12339"},{"key":"2026061814000752000_2026.06.13.732071v1.31","doi-asserted-by":"publisher","DOI":"10.1038\/nature06106"},{"key":"2026061814000752000_2026.06.13.732071v1.32","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2016.0299"},{"key":"2026061814000752000_2026.06.13.732071v1.33","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-026-02448-z"},{"key":"2026061814000752000_2026.06.13.732071v1.34","doi-asserted-by":"publisher","DOI":"10.64898\/2026.02.02.26345374"},{"key":"2026061814000752000_2026.06.13.732071v1.35","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0747-1"},{"key":"2026061814000752000_2026.06.13.732071v1.36","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09929-5"},{"key":"2026061814000752000_2026.06.13.732071v1.37","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-018-0531-2"},{"key":"2026061814000752000_2026.06.13.732071v1.38","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02023-7"},{"key":"2026061814000752000_2026.06.13.732071v1.39","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04597-1"},{"key":"2026061814000752000_2026.06.13.732071v1.40","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-04797-9"},{"key":"2026061814000752000_2026.06.13.732071v1.41","doi-asserted-by":"publisher","DOI":"10.1038\/8394"},{"key":"2026061814000752000_2026.06.13.732071v1.42","doi-asserted-by":"publisher","DOI":"10.1038\/s41579-023-00914-1"},{"key":"2026061814000752000_2026.06.13.732071v1.43","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.chom.2020.03.014","article-title":"The Biology of the HIV-1 Latent Reservoir and Implications for Cure Strategies","volume":"27","year":"2020","journal-title":"Cell Host and Microbe"},{"key":"2026061814000752000_2026.06.13.732071v1.44","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00347-16"},{"key":"2026061814000752000_2026.06.13.732071v1.45","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2019.01025"},{"key":"2026061814000752000_2026.06.13.732071v1.46","doi-asserted-by":"crossref","first-page":"2439","DOI":"10.1097\/QAD.0000000000002011","article-title":"Antibody-dependent cellular cytotoxicity in HIV infection","volume":"32","year":"2018","journal-title":"AIDS"},{"key":"2026061814000752000_2026.06.13.732071v1.47","doi-asserted-by":"publisher","DOI":"10.1016\/j.jim.2013.11.022"},{"key":"2026061814000752000_2026.06.13.732071v1.48","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43384-y"},{"key":"2026061814000752000_2026.06.13.732071v1.49","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1021\/acsinfecdis.2c00573","article-title":"Indirect Mechanisms of HIV-1 Evasion from Broadly Neutralizing Antibodies In Vivo","volume":"9","year":"2023","journal-title":"ACS Infect. Dis"},{"key":"2026061814000752000_2026.06.13.732071v1.50","doi-asserted-by":"crossref","first-page":"11226","DOI":"10.1038\/s41467-025-66321-7","article-title":"Minor SHIV variants abrogate protective efficacy of broadly neutralizing antibodies in rhesus macaques","volume":"16","year":"2025","journal-title":"Nat. Commun"},{"key":"2026061814000752000_2026.06.13.732071v1.51","doi-asserted-by":"crossref","first-page":"e1008434","DOI":"10.1371\/journal.pcbi.1008434","article-title":"Pre-existing resistance in the latent reservoir can compromise VRC01 therapy during chronic HIV-1 infection","volume":"16","year":"2020","journal-title":"PLoS computational biology"},{"key":"2026061814000752000_2026.06.13.732071v1.52","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1097\/COH.0000000000000798","article-title":"Development of screening assays for use of broadly neutralizing antibodies in people with HIV","volume":"18","year":"2023","journal-title":"Curr. Opin. HIV AIDS"},{"key":"2026061814000752000_2026.06.13.732071v1.53","doi-asserted-by":"crossref","first-page":"710012","DOI":"10.3389\/fimmu.2021.710012","article-title":"Modeling HIV-1 Within-Host Dynamics After Passive Infusion of the Broadly Neutralizing Antibody VRC01","volume":"12","year":"2021","journal-title":"Front Immunol"},{"key":"2026061814000752000_2026.06.13.732071v1.54","doi-asserted-by":"crossref","first-page":"e1011518","DOI":"10.1371\/journal.pcbi.1011518","article-title":"Modeling resistance to the broadly neutralizing antibody PGT121 in people living with HIV-1","volume":"20","year":"2024","journal-title":"PLOS Comput. Biol"},{"key":"2026061814000752000_2026.06.13.732071v1.55","doi-asserted-by":"crossref","unstructured":"Meijers, M. , Vanshylla, K. , Gruell, H. , Klein, F. & L\u00e4ssig, M. Predicting in vivo escape dynamics of HIV-1 from a broadly neutralizing antibody. Proceedings of the National Academy of Sciences of the United States of America 118, (2021).","DOI":"10.1073\/pnas.2104651118"},{"key":"2026061814000752000_2026.06.13.732071v1.56","doi-asserted-by":"crossref","first-page":"e1008064","DOI":"10.1371\/journal.pcbi.1008064","article-title":"Early exposure to broadly neutralizing antibodies may trigger a dynamical switch from progressive disease to lasting control of SHIV infection","volume":"16","year":"2020","journal-title":"PLoS computational biology"},{"key":"2026061814000752000_2026.06.13.732071v1.57","doi-asserted-by":"crossref","first-page":"e1007626","DOI":"10.1371\/journal.pcbi.1007626","article-title":"Mathematical modeling to reveal breakthrough mechanisms in the HIV Antibody Mediated Prevention (AMP) trials","volume":"16","year":"2020","journal-title":"PLoS computational biology"},{"key":"2026061814000752000_2026.06.13.732071v1.58","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf1279"},{"key":"2026061814000752000_2026.06.13.732071v1.59","doi-asserted-by":"publisher","DOI":"10.1038\/nature14411"},{"key":"2026061814000752000_2026.06.13.732071v1.60","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aad5752"},{"key":"2026061814000752000_2026.06.13.732071v1.61","doi-asserted-by":"publisher","DOI":"10.1038\/nm.4268"},{"key":"2026061814000752000_2026.06.13.732071v1.62","doi-asserted-by":"crossref","first-page":"e181496","DOI":"10.1172\/jci.insight.181496","article-title":"Virologic effects of broadly neutralizing antibodies VRC01LS and VRC07-523LS on chronic HIV-1 infection","volume":"10","year":"2025","journal-title":"JCI Insight"},{"key":"2026061814000752000_2026.06.13.732071v1.63","doi-asserted-by":"publisher","DOI":"10.1111\/cei.12692"},{"key":"2026061814000752000_2026.06.13.732071v1.64","doi-asserted-by":"crossref","first-page":"e1002493","DOI":"10.1371\/journal.pmed.1002493","article-title":"Safety and pharmacokinetics of the Fc-modified HIV-1 human monoclonal antibody VRC01LS: A Phase 1 open-label clinical trial in healthy adults","volume":"15","year":"2018","journal-title":"PLoS Medicine"},{"key":"2026061814000752000_2026.06.13.732071v1.65","doi-asserted-by":"crossref","first-page":"e667","DOI":"10.1016\/S2352-3018(19)30181-X","article-title":"Safety and pharmacokinetics of broadly neutralising human monoclonal antibody VRC07-523LS in healthy adults: a phase 1 dose-escalation clinical trial","volume":"6","year":"2019","journal-title":"Lancet Hiv"},{"key":"2026061814000752000_2026.06.13.732071v1.66","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.01814-24"},{"key":"2026061814000752000_2026.06.13.732071v1.67","doi-asserted-by":"publisher","DOI":"10.1371\/journal.ppat.1006478"},{"key":"2026061814000752000_2026.06.13.732071v1.68","first-page":"49","article-title":"A majority of HIV persistence during antiretroviral therapy is due to infected cell proliferation","volume":"9","year":"2018","journal-title":"Nature Communications"},{"key":"2026061814000752000_2026.06.13.732071v1.69","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1424184112"},{"key":"2026061814000752000_2026.06.13.732071v1.70","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.chembiol.2024.03.008","article-title":"SARS-CoV-2 resistance to monoclonal antibodies and small-molecule drugs","volume":"31","year":"2024","journal-title":"Cell Chem. Biol"},{"key":"2026061814000752000_2026.06.13.732071v1.71","doi-asserted-by":"publisher","DOI":"10.1101\/2025.08.29.673185"},{"key":"2026061814000752000_2026.06.13.732071v1.72","doi-asserted-by":"publisher","DOI":"10.1172\/JCI134395"},{"key":"2026061814000752000_2026.06.13.732071v1.73","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1097\/COH.0000000000000764","article-title":"A calculated risk: Evaluating HIV resistance to the broadly neutralising antibodies10-1074 and 3BNC117","volume":"17","year":"2022","journal-title":"Curr. Opin. HIV AIDS"},{"key":"2026061814000752000_2026.06.13.732071v1.74","first-page":"D202","article-title":"Predicting the broadly neutralizing antibody susceptibility of the HIV reservoir","volume":"4","year":"2019","journal-title":"JCI Insight"},{"key":"2026061814000752000_2026.06.13.732071v1.75","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01953-6"},{"key":"2026061814000752000_2026.06.13.732071v1.76","doi-asserted-by":"publisher","DOI":"10.1016\/j.virusres.2015.10.009"},{"key":"2026061814000752000_2026.06.13.732071v1.77","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.02425-16"},{"key":"2026061814000752000_2026.06.13.732071v1.78","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2018.00260"},{"key":"2026061814000752000_2026.06.13.732071v1.79","doi-asserted-by":"publisher","DOI":"10.1126\/science.aaf0972"},{"key":"2026061814000752000_2026.06.13.732071v1.80","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-34171-2"},{"key":"2026061814000752000_2026.06.13.732071v1.81","doi-asserted-by":"crossref","first-page":"e389","DOI":"10.1016\/S2352-3018(24)00090-0","article-title":"Dynamics of virological and immunological markers of HIV persistence after allogeneic haematopoietic stem-cell transplantation in the IciStem cohort: a prospective observational cohort study","volume":"11","year":"2024","journal-title":"Lancet HIV"},{"key":"2026061814000752000_2026.06.13.732071v1.82","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09893-0"},{"key":"2026061814000752000_2026.06.13.732071v1.83","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1717765115"},{"key":"2026061814000752000_2026.06.13.732071v1.84","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01876-15"},{"key":"2026061814000752000_2026.06.13.732071v1.85","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1172\/JCI122466","article-title":"Fc-dependent functions are redundant to efficacy of anti-HIV antibody PGT121 in macaques","volume":"129","year":"2018","journal-title":"J. Clin. Investig"},{"key":"2026061814000752000_2026.06.13.732071v1.86","doi-asserted-by":"crossref","unstructured":"Hangartner, L. et al. Effector function does not contribute to protection from virus challenge by a highly potent HIV broadly neutralizing antibody in nonhuman primates. Sci. Transl. Med. 13, (2021).","DOI":"10.1126\/scitranslmed.abe3349"},{"key":"2026061814000752000_2026.06.13.732071v1.87","doi-asserted-by":"publisher","DOI":"10.48550\/arxiv.1201.0490"},{"key":"2026061814000752000_2026.06.13.732071v1.88","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2109172119"},{"key":"2026061814000752000_2026.06.13.732071v1.89","doi-asserted-by":"crossref","unstructured":"Lavielle, M. Mixed Effects Models for the Population Approach: Models, Tasks, Methods and Tools. (CRC press, 2014).","DOI":"10.1201\/b17203"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.06.13.732071","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,18]],"date-time":"2026-06-18T21:00:39Z","timestamp":1781816439000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.06.13.732071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6,16]]},"references-count":89,"URL":"https:\/\/doi.org\/10.64898\/2026.06.13.732071","relation":{},"subject":[],"published":{"date-parts":[[2026,6,16]]},"subtype":"preprint"}}